Pinealon

Pinealon is a synthetic tripeptide, three amino acids long, sold as a neuroprotective and anti-ageing compound. The problem with its evidence is not the amount. There are papers, in indexed journals, with methods sections.

The problem is where they all come from. Pinealon belongs to a family of short peptides developed and studied almost entirely by one research school in St Petersburg, and reading the author lists across the literature is the quickest way to see it. The work is also still in cell culture thirteen years after the first mechanistic paper, and the single human study gave this peptide alongside another one, which means nothing in it can be attributed to pinealon.

Pinealon is the sequence glutamic acid, aspartic acid, arginine, often written EDR. Three residues is very short for a peptide with claimed regulatory activity, and that shortness is part of the proposed mechanism rather than an accident.

It is one of a set. The same school produced epitalon, vilon, vesugen, testagen, cortagen and others, described collectively as peptide bioregulators, each assigned an organ or system. Epitalon has its own entry in this library and comes from the same source. Recognising that these are a product family from one institution rather than independent discoveries is the single most useful thing a reader can take from this page, because it applies to every one of them.

Where the Biology Gets Interesting

There is no established endogenous role. Pinealon is a designed molecule rather than something isolated from human tissue and then characterised, so the question is not what it does in the body but whether supplying it produces the claimed effects.

The proposed answer is unusual and worth understanding, because it is the interesting part. Short peptides of this kind are said to enter the cell nucleus and interact directly with DNA, influencing which genes are expressed. Fluorescence-labelled work from the same group reports the peptides reaching the nucleus and nucleolus in cultured cells. If that account held broadly it would be a genuinely novel class of regulator, which is a large claim and one that has stayed within the literature that proposed it.

The Mechanism, Without Overstating It

The account given by the group that developed the peptide is that it activates expression of genes and synthesis of proteins involved in maintaining neuronal activity, and reduces the rate at which neurons die under stress. Supporting observations include concentration-dependent restriction of reactive oxygen species accumulation in cerebellar granule cells, neutrophils and a pheochromocytoma cell line under induced oxidative stress.

Two things are worth holding alongside that. The first is that the group proposing the mechanism and the group testing it are the same, which is normal early in a research programme and becomes a problem when it stays that way for two decades. The second is that the most recent work, in 2024, used neurons transdifferentiated from the skin cells of elderly donors and found the peptide reduced oxidative DNA damage and promoted dendritic branching while leaving mitochondrial activity, lysosomal activity and the senescence marker p16 unchanged. That is a mixed result, reported honestly, and still in culture.

The overreach on this compound has a different shape from most, and it survives citation-checking, which is what makes it worth spelling out.

The first and largest issue is provenance. Two structured literature searches for this entry returned twenty-two distinct results, and every preclinical study of pinealon traced to one research school or its immediate collaborators. That is a search result rather than proof that no independent work exists, and it is stated that way deliberately. But a body of evidence produced almost entirely by the people who developed and named the compound is weaker than the same number of papers from unrelated groups, and no amount of internal consistency fixes that.

The second is that the work has not moved. The mechanistic cell paper is from 2011 and the most recent paper, from 2024, is still cell culture. Thirteen years is long enough for a promising preclinical result to reach a controlled human trial if it was going to.

The third is the human study, which cannot carry the weight placed on it. Two peptides given together, a composite index as the endpoint, and thirty-two participants.

The fourth is that the mechanism proposed is a large claim. A three-residue peptide entering the nucleus and regulating gene expression would be a novel class of regulator, and claims of that size need corroboration from outside the group making them.

There is no standalone human safety record. The one human study gave pinealon together with another peptide in thirty-two people, which cannot separate the safety of either, and no other human work was located. Nothing can be said about tolerance, adverse effects, or what happens over any extended period.

The laboratory work does not report obvious toxicity, and it would be unfair to imply otherwise, but absence of reported harm in cell culture and short rodent studies is a weak basis for any statement about people. There is no approved pinealon product anywhere, so material sold outside a research setting carries the usual identity and purity questions with nothing to compare it against, and this family of peptides is sold widely enough that the question is not hypothetical.

On the regulators, both axes are simply blank. Pinealon appears nowhere in the FDA 503A nominations, in any category, and absence there carries no information about safety. It is not named on the 2026 WADA Prohibited List either, which is not permission: S0 prohibits at all times any substance with no current approval by any regulator for human therapeutic use.

Read honestly, this entry supports statements about cells and rats and almost nothing about people. A short synthetic peptide limits accumulation of reactive oxygen species in several cultured cell types under induced stress, was associated with better cognitive outcomes in the offspring of rats subjected to a severe prenatal insult, and reduced one marker of oxidative DNA damage in cultured neurons derived from elderly donors while leaving several other ageing markers unchanged.

What it does not support is any claim about cognition, ageing or resilience in a person. The useful takeaway is a habit rather than a conclusion. When a compound arrives with a citation list, the references being real is the beginning of the check and not the end of it. Where they came from, what species they were done in, and whether anyone outside the originating group has reproduced them are the questions that decide what the citations are worth.

Not independently corroborated in this review. Two structured literature searches returned twenty-two distinct results and every preclinical study traced back to one research school or its immediate collaborators, which is a search result rather than proof that no outside work exists.

Not tested in humans on its own. The single human study gave pinealon together with a second peptide in thirty-two people and used a composite biological-age index as its endpoint, so nothing in it can be attributed to this compound.

Not a compound whose research has progressed. The mechanistic cell work dates from 2011 and the most recent study, in 2024, is still cell culture, which is a long time for a promising preclinical result to stay in a dish.

Not separable from the rest of its family. Epitalon, vilon, vesugen and the others come from the same institution and share the same evidentiary situation, so a judgement about one of them is largely a judgement about all of them.

Not a protocol or personal-use guide. Almost the entire literature here is preclinical and concentrated in one research tradition with little independent replication, which is a reason to describe it and not to act on it.

Pinealon is the hardest compound in this library to dismiss quickly and one of the least supportable once examined, because its weakness is invisible to the checks most readers perform. The citations are real. The journals are indexed. The methods are described. Someone verifying the references would come away reassured.

What that check misses is that a body of work produced almost entirely by the group that created and named the compound is not independent evidence, however internally consistent it is, and that research still in cell culture after thirteen years has told you something by not moving. We cover pinealon because checking provenance is a harder skill than checking citations, and this is the clearest example on the site of why the second check is not enough on its own.